|1.||von Deimling, Andreas: 26 articles (02/2015 - 12/2008)|
|2.||Kato, Yukinari: 17 articles (10/2015 - 12/2009)|
|3.||Capper, David: 15 articles (02/2015 - 10/2009)|
|4.||Hartmann, Christian: 15 articles (12/2014 - 12/2008)|
|5.||Yan, Hai: 14 articles (01/2016 - 02/2009)|
|6.||Wick, Wolfgang: 14 articles (02/2015 - 10/2009)|
|7.||Weller, Michael: 13 articles (11/2015 - 10/2009)|
|8.||Reifenberger, Guido: 13 articles (12/2014 - 10/2009)|
|9.||Lai, Albert: 11 articles (09/2015 - 05/2011)|
|10.||Park, Jeen-Woo: 11 articles (08/2014 - 03/2002)|
11/01/2011 - "Similarly, the R132H isocitrate dehydrogenase 1 IDH1 mutation, which can now be detected by use of a specific antibody, predicts better outcome in gliomas. "
08/01/2015 - "Collective tissue banking, large-scale genomic, transcriptomic and methylomic expression profiling, and discoveries such as isocitrate dehydrogenase gene mutation and the C-phosphate-G island methylation phenotype have improved glioma classification schemes. "
02/01/2015 - "Isocitrate dehydrogenase 1 (IDH1) mutations have been discovered frequently in glioma patients and are strongly correlated with improved survival. "
02/01/2015 - "Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas."
01/01/2015 - "The purpose of our study was to explore the difference between isocitrate dehydrogenase (IDH)-1/2 gene mutation-positive and -negative high-grade gliomas (HGGs) using histogram analysis of apparent diffusion coefficient (ADC) and normalized cerebral blood volume (nCBV) maps. "
03/30/2012 - "Here, we discuss how recent sequencing studies are identifying unexpected drivers of gliomagenesis, including mutations in isocitrate dehydrogenase 1 and the NF-κB pathway, and how genome-wide analyses are reshaping the classification schemes for tumors and enhancing prognostic value of molecular markers. "
03/01/2012 - "Pathologic diversity of glioneuronal tumor with neuropil-like islands: a histological and immunohistochemical study with a special reference to isocitrate dehydrogenase 1 (IDH1) in 5 cases."
11/15/2015 - "Isocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer to IDH1(R132H), a structural alteration that leads to catalysis of α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate. "
11/01/2015 - "Mutations in isocitrate dehydrogenase 1/2 (IDH1/2(MT)) are drivers of a variety of myeloid neoplasms. "
10/01/2015 - "Moreover, due to the fact that mutations in the Isocitrate dehydrogenase (IDH-1 and IDH-2) genes are more frequent in our IH-CCA than in our EH-CCA samples, we suggest that the tumor subtypes have a different molecular profile. "
|3.||Glioblastoma (Glioblastoma Multiforme)
12/01/2013 - "Previous studies proposed that isocitrate dehydrogenase 1 (IDH1) mutation was associated with improved survival in patients with glioblastoma, but those studies reported varying estimates and yielded inconclusive results. "
08/01/2015 - "The aim of this study was to explore the difference in high mobility group A1 (HMGA1) expression and isocitrate dehydrogenase (IDH) 1 R132H point mutation in initial and recurrent glioblastoma multiforme (GBM), and to further identify whether the expression of HMGA1 has a role in the malignant progression of GBM. "
04/01/2013 - "The purpose of this study was to distinguish pseudoprogression (PP) from early true progression in patients with glioblastoma (GBM) based on the presence of a mutation in isocitrate dehydrogenase 1 (IDH1). "
02/01/2012 - "Recent studies have shown that isocitrate dehydrogenase 1/2 (IDH1/2) mutations occur frequently in secondary glioblastoma. "
12/01/2008 - "A recent study reported on mutations in the active site of the isocitrate dehydrogenase (IDH1) gene in 12% of glioblastomas. "
|4.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
03/01/2012 - "Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission."
06/01/2013 - "This study was purpose to analyze the frequency and of isocitrate dehydrogenase 2 (IDH2) gene mutation in acute myeloid leukemia (AML) and its clinic significance. "
12/01/2012 - "This study was purposed to detect the mutation of isocitrate dehydrogenase 1 (IDH-1) gene in patients with acute myeloid leukemia (AML) and to explore its clinical significance. "
08/01/2011 - "The purpose of this study was to identify point mutation of the isocitrate dehydrogenase gene (IDH1 and IDH2) in patients with acute myeloid leukemia(AML) and its clinical significance. "
07/14/2011 - "We have investigated the prognostic significance of isocitrate dehydrogenase 2 (IDH2) mutations in 1473 younger adult acute myeloid leukemia patients treated in 2 United Kingdom Medical Research Council trials. "
|5.||Hearing Loss (Hearing Impairment)
|1.||DNA (Deoxyribonucleic Acid)
|2.||Biological Markers (Surrogate Marker)
|4.||Drug Therapy (Chemotherapy)
|5.||Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)